Market brief

European Sterile Fill-Finish CDMO 2026: Aseptic Injectables, Vaccines, Biologics, and ATMP Sterile Capacity

European sterile fill-finish CDMO capacity in 2026 spans 13 directory-surfaced operators across three overlapping tracks: large-cap aseptic injectables + biologics fill-finish (Vetter Pharma, FUJIFILM Diosynth Hillerød, Boehringer Ingelheim, Recipharm), viral vaccine + ATMP fill-finish (IDT Biologika, Bavarian Nordic, Valneva, 3P Biovian, Kuopio Center for Gene and Cell Therapy), and Baltic + Polish sterile dosage + hospital medicines (Pharmidea, Kalceks, Polpharma Starogard Gdański, Northway Biotech). Germany hosts the directory’s anchor large-cap aseptic fill-finish operator (Vetter Pharma, Ravensburg) plus viral-vaccine fill-finish (IDT Biologika, Dessau-Roßlau) and Boehringer Ingelheim biopharmaceutical production. Denmark adds vaccine fill-finish + biodefense (Bavarian Nordic, Kvistgård) and biologics CDMO fill-finish (FUJIFILM Diosynth, Hillerød). Finland adds aseptic fill-finish through 3P Biovian (Turku) and viral-vector ATMP fill-finish through Kuopio Center for Gene and Cell Therapy. The Baltic + Polish layer (Pharmidea, Kalceks, Polpharma, Northway Biotech) covers sterile dosage forms + hospital medicines + biopharm fill-finish for regional supply. Adjacent operators in primary packaging + drug-delivery devices (Gerresheimer, Ypsomed, SCHOTT-adjacent) are covered in the European Pharma Cold Chain Logistics 2026 and European Cardiometabolic Therapeutics 2026 briefs.

Summary

Key findings

Vetter Pharma (Ravensburg, Germany) is the directory-surfaced large-cap aseptic fill-finish operator for injectables - supplying syringe, cartridge, and vial fill-finish at commercial scale to global pharma sponsors across biologics + small-molecule injectables.
IDT Biologika (Dessau-Roßlau, Germany) is the directory-surfaced viral-vaccine + CGT fill-finish CDMO with capacity across viral vaccines, cell and gene therapy, and fill-finish operations including pandemic-era COVID-19 manufacturing.
Denmark hosts FUJIFILM Diosynth Biotechnologies (Hillerød) for large-scale biologics CDMO + commercial biopharmaceutical manufacturing + fill-finish, alongside Bavarian Nordic (Kvistgård) for vaccine fill-finish + biodefense manufacturing including MVA-BN smallpox / mpox vaccine.
The Baltic + Polish + Nordic sterile dosage + hospital-medicines layer concentrates at Pharmidea (Olaine, Latvia, sterile products), Kalceks (Riga, Latvia, sterile dosage forms + hospital medicines), Polpharma Starogard Gdański (Poland, sterile production + APIs), Recipharm (Stockholm, sterile CDMO), and Northway Biotech (Vilnius, biopharmaceuticals).
First-pass shortlist

Start with the product path, not the phrase “fill-finish”

Sterile fill-finish is not one interchangeable service. Route the first call through presentation, modality, scale, and the handoff from drug substance. The entries below are source-backed starting points, not a capacity ranking or confirmation of current campaign availability.

Commercial injectables

Prefilled syringes, cartridges, and vials at larger scale

Germany

Publicly stated scope
Start with Vetter Pharma for publicly stated commercial aseptic injectable fill-finish across syringes, cartridges, and vials for biologics and small-molecule injectables.
Confirm first
Primary container and closure, fill volume, formulation, visual inspection, device assembly, cold-chain requirements, batch scale, and the drug-substance handoff.
Do not assume
That syringe, cartridge, or vial capability automatically covers the specific presentation, device combination, inspection regime, or open production window.
Integrated biologics

Drug substance plus commercial biologics fill-finish

Denmark and Germany

Publicly stated scope
Start with FUJIFILM Diosynth Biotechnologies Hillerød for its publicly described large-scale biologics process-development, manufacturing, and fill-finish scope; compare against the relevant Boehringer Ingelheim route where an integrated biologics partner is needed.
Confirm first
Whether both drug substance and drug product can be handled at the same site, plus cell line, scale, technology-transfer, analytical, and release-testing responsibilities.
Do not assume
That an integrated corporate offering removes the need to verify site-level scope, programme acceptance, or every downstream packaging requirement.
Vaccines or ATMP

Viral vaccines, vector programmes, and cell or gene therapy product

Germany, Denmark, and Finland

Publicly stated scope
Start with IDT Biologika for viral-vaccine and cell-and-gene-therapy scope, then assess Bavarian Nordic, 3PBIOVIAN, and Kuopio Center for Gene and Cell Therapy against the specific vaccine, vector, or ATMP pathway.
Confirm first
Modality, containment and biosafety requirements, vector or cell handling, aseptic presentation, comparability package, release testing, and the division of responsibilities across sites.
Do not assume
That vaccine, vector, or ATMP wording means interchangeable capabilities across all products or a ready-to-contract GMP campaign.
Regional sterile supply

Hospital medicines, ophthalmics, and regional sterile dosage forms

Latvia, Poland, and Lithuania

Publicly stated scope
Start with Pharmidea for sterile injectable and ophthalmic products, Kalceks for sterile dosage forms and hospital medicines, Polpharma for integrated Polish sterile production, or Northway Biotech for biopharmaceutical regional supply.
Confirm first
Target market, dosage form, product classification, required site authorization, scale, artwork and packaging responsibilities, and whether the operator accepts external CDMO work.
Do not assume
That a manufacturer’s own hospital-medicine or generics portfolio proves external capacity for a different product and market.
Cross-modality supply

A broader CDMO network or a route requiring multiple handoffs

Europe-wide

Publicly stated scope
Start with Recipharm for a broader CDMO and sterile-manufacturing discussion when the programme may need more than one modality or site, then map the exact sterile operation separately.
Confirm first
Which legal entity and site would manufacture each stage, how the transfer and quality agreement are structured, and what remains with external packaging or logistics partners.
Do not assume
That a network-level service description is a substitute for a named site, product-specific quality package, and documented manufacturing path.
Numbers

Quick numbers

Sterile fill-finish operators13Across aseptic injectables, vaccines, ATMP, and Baltic + Polish sterile dosage
Aseptic injectable fill-finish anchorVetter Pharma (Ravensburg)Large-cap PFS + cartridge + vial fill-finish
Vaccine + ATMP fill-finish operators5 operatorsIDT Biologika + Bavarian Nordic + Valneva + 3P Biovian + Kuopio Center for Gene and Cell Therapy
Baltic + Polish sterile cluster4 operatorsPharmidea + Kalceks + Polpharma Starogard + Northway Biotech
Analysis

Vetter Pharma and the German aseptic fill-finish anchor

Germany concentrates the directory-surfaced large-cap aseptic fill-finish capacity. Vetter Pharma (Ravensburg) is the directory’s anchor aseptic injectable fill-finish operator, providing prefilled syringe, cartridge, and vial sterile fill-finish at commercial scale for biologics + small-molecule injectables. Vetter operates clinical and commercial manufacturing sites across Ravensburg (Schützenstraße HQ + Ravensburg South) and Langenargen alongside US sites - the directory entry covers the German anchor. IDT Biologika (Dessau-Roßlau) provides viral vaccine + cell and gene therapy + fill-finish CDMO services with experience across COVID-19 vaccine fill-finish + adjuvanted vaccines + viral-vector therapeutics. Boehringer Ingelheim (Ingelheim am Rhein) runs biopharmaceutical production + therapeutic manufacturing including in-house and contract biologics fill-finish at scale.

Analysis

Danish biologics CDMO + vaccine fill-finish

Denmark hosts two directory operators in biologics + vaccine fill-finish. FUJIFILM Diosynth Biotechnologies Hillerød is the directory-surfaced large-scale biologics CDMO providing process development + commercial biopharmaceutical manufacturing + fill-finish, originally a Biogen biopharmaceutical site, acquired by FUJIFILM in August 2019 and now part of the FUJIFILM Diosynth global network with major capacity expansions announced 2021–2024. Bavarian Nordic (Kvistgård) develops and manufactures vaccines including the MVA-BN platform (Jynneos / Imvanex / Imvamune for smallpox + mpox, FDA + EMA approved) plus biodefense vaccines + chikungunya vaccine Vimkunya (FDA approved February 2025) - including in-house fill-finish operations.

Analysis

Finnish + Baltic ATMP and viral-vector fill-finish

Finland and the Baltics add ATMP and biopharm fill-finish capacity. 3P Biovian (Turku, Finland) is the merged Spanish + Finnish CDMO providing biologics + viral vectors + plasmid DNA + aseptic fill-finish using mammalian and microbial platforms - the Turku site provides aseptic fill-finish for biologics + viral-vector ATMP. Kuopio Center for Gene and Cell Therapy (Kuopio, Finland) provides GMP viral-vector manufacturing + AAV + adenovirus + lentivirus + ATMP CDMO services including ATMP fill-finish for cell + gene therapy programmes - the directory-surfaced Finnish ATMP CDMO. Northway Biotech (Vilnius, Lithuania) provides biopharm CDMO + cell line development + biologics manufacturing including aseptic fill-finish for regional supply. The Cell & Gene Therapy Europe 2026 brief covers the wider ATMP CDMO layer including Antion Biosciences and Fuse Vectors.

Analysis

Baltic + Polish sterile dosage + hospital medicines

The Baltic + Polish sterile dosage + hospital-medicines layer concentrates at four directory operators. Pharmidea (Olaine, Latvia) develops and manufactures sterile pharmaceutical products including injectable + ophthalmic + hospital medicines. Kalceks (Riga, Latvia) is the directory-surfaced Latvian sterile dosage forms + hospital medicines + finished dosage manufacturer. Polpharma Starogard Gdański (Poland) is the largest Polish pharmaceutical manufacturer providing sterile production + generics + APIs + drug development at integrated scale. Lotos Pharma (Mārupe, Latvia) provides pharmaceutical manufacturing + consumer health adjacent to the sterile dosage layer. The Polish Biotech Landscape 2026 brief covers Polpharma + Polpharma Biologics in wider context.

Analysis

Nordic sterile manufacturing + vaccine fill-finish

Sweden and Finland add Nordic sterile manufacturing + vaccine fill-finish. Recipharm (Stockholm) provides CDMO operations + sterile manufacturing + pharmaceutical supply across multiple modalities for global sponsors. Valneva (Solna manufacturing site, Sweden; HQ Saint-Herblain, France) develops and manufactures vaccines including IXIARO (Japanese encephalitis), DUKORAL (cholera), and IXCHIQ (chikungunya, FDA + EMA approved 2023–2024) with vaccine fill-finish capacity at its Solna + European sites. The European Vaccines Landscape 2026 brief covers Valneva and Bavarian Nordic in wider vaccine context.

Analysis

Adjacent: primary packaging, drug delivery, and cold chain

European sterile fill-finish connects to a primary-packaging + drug-delivery device + cold-chain ecosystem covered in adjacent briefs. Gerresheimer (Düsseldorf, Germany) provides primary packaging + drug delivery systems including vials, syringes, and cartridges for sterile manufacturing - covered in the European Cardiometabolic Therapeutics 2026 brief. Ypsomed (Burgdorf, Switzerland) provides autoinjector + pen + pump device platforms - covered in cardiometabolic context. The European Pharma Cold Chain Logistics 2026 brief covers GDP-aligned distribution of fill-finished sterile products. The European CDMO Capacity 2026 brief covers the wider European CDMO layer including Lonza Visp, Wacker Biotech, AGC Biologics, and integrated biologics CDMO.

Analysis

How to pick a European sterile fill-finish CDMO partner in 2026

Match the decision to the modality + scale. Large-cap aseptic injectable fill-finish (prefilled syringes, cartridges, vials, biologics + small molecule): Vetter Pharma (Ravensburg). Viral vaccine + CGT + adjuvanted vaccine fill-finish: IDT Biologika (Dessau-Roßlau). Large-scale biologics CDMO + commercial biopharma + fill-finish: FUJIFILM Diosynth Biotechnologies (Hillerød). Vaccine + biodefense fill-finish (MVA-BN, chikungunya): Bavarian Nordic (Kvistgård). In-house biopharmaceutical production + therapeutic manufacturing: Boehringer Ingelheim (Ingelheim am Rhein). Sterile CDMO + cross-modality supply: Recipharm (Stockholm). Aseptic fill-finish + viral-vector + plasmid DNA CDMO: 3P Biovian (Turku). ATMP cell + gene therapy fill-finish: Kuopio Center for Gene and Cell Therapy (Kuopio). Biopharm CDMO + biologics fill-finish for Baltic regional supply: Northway Biotech (Vilnius). Sterile pharmaceutical products + injectable + ophthalmic: Pharmidea (Olaine). Sterile dosage forms + hospital medicines: Kalceks (Riga). Integrated Polish sterile production + APIs + generics at scale: Polpharma Starogard Gdański. Vaccine commercial fill-finish + Japanese encephalitis + cholera + chikungunya: Valneva (Solna, Sweden manufacturing site). The European CDMO Capacity 2026 brief covers cross-modality CDMO selection.

What to watch

What to watch next

Vetter Pharma capacity expansion + new commercial fill-finish customer disclosures
IDT Biologika viral-vaccine + CGT fill-finish growth post-COVID-era ramp
FUJIFILM Diosynth Hillerød ongoing capacity expansion announcements
Bavarian Nordic Vimkunya chikungunya + MVA-BN platform commercial expansion
Valneva IXCHIQ chikungunya commercial rollout + new vaccine pipeline
3P Biovian + Kuopio Center for Gene and Cell Therapy ATMP fill-finish capacity additions
Polpharma + Pharmidea + Kalceks Baltic + Polish sterile dosage capacity disclosures
FAQ

Frequently asked questions

Who is the main European aseptic fill-finish CDMO in 2026?

Vetter Pharma (Ravensburg, Germany) is the directory-surfaced large-cap aseptic injectable fill-finish operator providing prefilled syringe, cartridge, and vial sterile fill-finish at commercial scale to global pharma sponsors across biologics + small-molecule injectables. For sponsors evaluating European aseptic injectable fill-finish partnership at commercial scale, Vetter is the directory’s primary German operator. IDT Biologika (Dessau-Roßlau) is the dedicated viral-vaccine + CGT fill-finish operator. FUJIFILM Diosynth (Hillerød) is the dedicated large-scale biologics CDMO + fill-finish operator.

Where does European vaccine fill-finish concentrate?

Five directory operators run vaccine + ATMP fill-finish. IDT Biologika (Dessau-Roßlau) for viral vaccines + adjuvanted vaccines + cell and gene therapy. Bavarian Nordic (Kvistgård) for MVA-BN platform vaccines (Jynneos / Imvanex smallpox/mpox, Vimkunya chikungunya 2025) + biodefense. Valneva (Solna, Sweden manufacturing site) for IXIARO, DUKORAL, IXCHIQ chikungunya. 3P Biovian (Turku) for biologics + viral vector + aseptic fill-finish. Kuopio Center for Gene and Cell Therapy (Kuopio) for ATMP cell + gene therapy fill-finish.

Who runs the European biologics CDMO + fill-finish at large scale?

FUJIFILM Diosynth Biotechnologies Hillerød (Denmark) is the directory-surfaced large-scale biologics CDMO providing process development + commercial biopharmaceutical manufacturing + fill-finish, originally a Biogen biopharmaceutical site (acquired by FUJIFILM in August 2019) and now part of the FUJIFILM Diosynth global network with major capacity expansions announced 2021-2024. Boehringer Ingelheim (Ingelheim am Rhein) runs in-house and contract biopharmaceutical production + therapeutic manufacturing at scale.

Where is the Baltic + Polish sterile dosage + hospital medicines layer?

Four directory operators. Pharmidea (Olaine, Latvia) develops and manufactures sterile pharmaceutical products including injectable + ophthalmic + hospital medicines. Kalceks (Riga, Latvia) is the directory-surfaced Latvian sterile dosage forms + hospital medicines + finished dosage manufacturer. Polpharma Starogard Gdański (Poland) is the largest Polish pharmaceutical manufacturer providing sterile production + generics + APIs + drug development at integrated scale. Northway Biotech (Vilnius, Lithuania) provides biopharm CDMO including aseptic fill-finish for regional supply.

How do drug-delivery devices and cold chain connect to fill-finish?

European sterile fill-finish connects to primary-packaging + drug-delivery + cold-chain ecosystems covered in adjacent briefs. Gerresheimer (Düsseldorf) provides primary packaging including vials + syringes + cartridges. Ypsomed (Burgdorf) provides autoinjector + pen + pump device platforms used downstream of fill-finish for biologics + insulin + GLP-1 administration. The European Pharma Cold Chain Logistics 2026 brief covers GDP-aligned distribution of fill-finished sterile products including DHL Health Logistics, Kuehne+Nagel Healthcare, and World Courier.

Methodology note

Sources and interpretation

Sources: verified Memel Biotech directory entries for every sterile fill-finish + biologics CDMO + vaccine manufacturing operator, official company disclosures + capacity announcements, EMA + FDA approval records (Jynneos, Vimkunya, IXCHIQ, IXIARO, DUKORAL), and editorial cross-reference against the European CDMO Capacity 2026, European Vaccines Landscape 2026, Cell & Gene Therapy Europe 2026, European Pharma Cold Chain Logistics 2026, German Biotech Landscape 2026, Nordic Biotech Landscape 2026, and Baltic Biotech Landscape 2026 briefs. The directory entry for each operator links to the authoritative company sources.

Disclaimer

Use limits

This brief is an editorial map of visible European sterile fill-finish CDMO + biologics manufacturing capacity in 2026. Capacity claims, capability descriptions, and approval records reflect publicly disclosed information as of directory review - verify directly with each operator before engagement. Sterile fill-finish supply is highly project-specific and subject to capacity allocation cycles.

Primary sources

Source list

Vetter PharmaIDT BiologikaFUJIFILM Diosynth BiotechnologiesBavarian NordicVetter Ravensburg site overview
Related pages

Related directory records

Verification methodologyLithuania biotech page (LT)
Briefs

Continue through related topics.

A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.

All briefsDirectory home